Clinical Trial

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-25
Trial Details
NCT Number NCT07463573
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment 466 participants
Start Date 2026-04-20
Primary Completion 2028-06-05 (estimated)
Study Completion 2029-07-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-24